JP2023537316A5 - - Google Patents
Info
- Publication number
- JP2023537316A5 JP2023537316A5 JP2023506315A JP2023506315A JP2023537316A5 JP 2023537316 A5 JP2023537316 A5 JP 2023537316A5 JP 2023506315 A JP2023506315 A JP 2023506315A JP 2023506315 A JP2023506315 A JP 2023506315A JP 2023537316 A5 JP2023537316 A5 JP 2023537316A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- histidine
- seq
- pharmaceutical preparation
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063059502P | 2020-07-31 | 2020-07-31 | |
| US63/059,502 | 2020-07-31 | ||
| PCT/US2021/044043 WO2022026914A1 (en) | 2020-07-31 | 2021-07-30 | Anti-connexin antibody formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023537316A JP2023537316A (ja) | 2023-08-31 |
| JP2023537316A5 true JP2023537316A5 (cg-RX-API-DMAC7.html) | 2024-08-07 |
Family
ID=80002768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023506315A Pending JP2023537316A (ja) | 2020-07-31 | 2021-07-30 | 抗コネキシン抗体製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11912764B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4188544A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023537316A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230042744A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116234576A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021316119A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3190474A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300245A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022026914A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116854816A (zh) * | 2018-04-02 | 2023-10-10 | 阿拉玛布治疗学股份有限公司 | 连接蛋白43抗体及其用途 |
| AU2020219112A1 (en) * | 2019-02-04 | 2021-08-26 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| IL300245A (en) | 2020-07-31 | 2023-03-01 | Alamab Therapeutics Inc | Anti-connexin antibody formulations |
| US20250277017A1 (en) * | 2022-04-29 | 2025-09-04 | Board Of Regents, The University Of Texas System | Compositions and methods for treating eye diseases |
| WO2025006774A1 (en) * | 2023-06-30 | 2025-01-02 | Alamab Therapeutics, Inc. | Method of treating osteoarthritis |
| EP4761813A1 (en) * | 2023-08-14 | 2026-06-24 | Alamab Therapeutics, Inc. | Method of treating stroke |
| WO2025245485A1 (en) * | 2024-05-24 | 2025-11-27 | Alamab Therapeutics, Inc. | Method of treating bone cancers |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101573131B (zh) | 2005-02-03 | 2017-12-01 | 科达治疗有限公司 | 抗‑连接蛋白化合物及其治疗应用 |
| EP1865986B1 (en) * | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| WO2009148613A1 (en) | 2008-06-04 | 2009-12-10 | Coda Therapeutics, Inc. | Treatment of pain with gap junction modulation compounds |
| CN102413839A (zh) * | 2009-03-06 | 2012-04-11 | 医学免疫有限责任公司 | 人源化抗cd19抗体制剂 |
| US8956868B2 (en) | 2010-12-27 | 2015-02-17 | Lsip, Llc | Induced pluripotent stem cells produced with a connexin inhibitor and a TGF-β signaling inhibitor |
| WO2015027120A1 (en) | 2013-08-21 | 2015-02-26 | Jiang Jean X | Compositions and methods for targeting connexin hemichannels |
| US9493552B2 (en) | 2013-11-15 | 2016-11-15 | China Synthetic Rubber Corporation | Therapeutic biologic for treatment of hepatocellular carcinoma |
| WO2016029191A2 (en) | 2014-08-22 | 2016-02-25 | Auckland Uniservices Limited | Channel modulators |
| EP3394099A4 (en) * | 2015-12-22 | 2019-11-27 | Merck Sharp & Dohme Corp. | Formulations of Manipulated Anti- IL-10 Antibodies |
| BR112018017031A2 (pt) * | 2016-02-23 | 2019-01-22 | Sesen Bio Inc | formulações de antagonista de il-6 e usos das mesmas |
| AU2017224122B2 (en) * | 2016-02-26 | 2024-04-11 | The Board Of Regents Of The University Of Texas System | Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof |
| WO2017190152A1 (en) | 2016-04-29 | 2017-11-02 | Ocunexus Therapeutics, Inc. | Sustained release drug delivery devices |
| JOP20170170B1 (ar) | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| TWI911431B (zh) * | 2017-03-01 | 2026-01-11 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| US11603407B2 (en) * | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| MA49960A (fr) * | 2017-08-25 | 2021-06-02 | Omeros Corp | Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes de traitement de sujets souffrant d'un syndrome hémolytique atypique |
| CN116854816A (zh) * | 2018-04-02 | 2023-10-10 | 阿拉玛布治疗学股份有限公司 | 连接蛋白43抗体及其用途 |
| MX2021005708A (es) * | 2018-11-16 | 2021-09-21 | Bristol Myers Squibb Co | Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos. |
| AU2020219112A1 (en) * | 2019-02-04 | 2021-08-26 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| CA3156812A1 (en) * | 2019-10-02 | 2021-04-08 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
| IL300245A (en) | 2020-07-31 | 2023-03-01 | Alamab Therapeutics Inc | Anti-connexin antibody formulations |
-
2021
- 2021-07-30 IL IL300245A patent/IL300245A/en unknown
- 2021-07-30 CN CN202180062049.8A patent/CN116234576A/zh active Pending
- 2021-07-30 AU AU2021316119A patent/AU2021316119A1/en active Pending
- 2021-07-30 CA CA3190474A patent/CA3190474A1/en active Pending
- 2021-07-30 WO PCT/US2021/044043 patent/WO2022026914A1/en not_active Ceased
- 2021-07-30 EP EP21851080.8A patent/EP4188544A4/en active Pending
- 2021-07-30 KR KR1020237006832A patent/KR20230042744A/ko active Pending
- 2021-07-30 JP JP2023506315A patent/JP2023537316A/ja active Pending
- 2021-07-30 US US17/390,635 patent/US11912764B2/en active Active
-
2024
- 2024-01-17 US US18/415,511 patent/US20240309085A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022552152A5 (cg-RX-API-DMAC7.html) | ||
| JP6836500B2 (ja) | 自己免疫状態および炎症状態を治療するための方法および組成物 | |
| JP7593979B2 (ja) | バイオフィルムの除去のためのペプチドおよび抗体 | |
| EP3380518B1 (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| JP2025122007A (ja) | Burkholderia感染の処置のための組成物および方法 | |
| JP7627255B2 (ja) | バイオフィルムを破壊するための抗体組成物 | |
| ES2965283T3 (es) | Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento | |
| JP2021512881A5 (cg-RX-API-DMAC7.html) | ||
| EP2099489B1 (en) | Compositions and methods for treating a neoplasm | |
| ES2734886T3 (es) | Anticuerpos anti-clusterina y fragmentos de unión a antígeno y su uso para reducir el volumen tumoral | |
| ES2543095T3 (es) | Agentes de unión a TLR3 | |
| JP2023517234A5 (cg-RX-API-DMAC7.html) | ||
| TW200900420A (en) | Hepcidin, hepcidin antagonists and methods of use | |
| EA028574B1 (ru) | Способ лечения b-клеточных злокачественных новообразований, экспрессирующих cd19 | |
| UA129282C2 (uk) | Спосіб лікування або профілактики пов'язаних з c5 хвороб | |
| ES2994131T3 (en) | Compositions and methods for treating cancer | |
| JP2024506940A5 (cg-RX-API-DMAC7.html) | ||
| CN116585468A (zh) | 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途 | |
| JP2022105056A (ja) | 高濃度の抗vegf抗体を含有するタンパク質溶液製剤 | |
| TW202003046A (zh) | 以鉑為主之劑與抗組織因子抗體-藥物共軛物的組合治療癌症之方法 | |
| ES2855973T3 (es) | Nuevo anticuerpo útil en trastornos neurológicos o neurodegenerativos | |
| EA200501131A1 (ru) | Парентеральные композиции пептидов для лечения системной красной волчанки | |
| JP2023553538A5 (cg-RX-API-DMAC7.html) | ||
| US20230242626A1 (en) | Composition for treatment and prevention of covid-19 | |
| CN112533639A (zh) | 掩蔽的抗体的药物配制品 |